Verici Dx (LSE:VRCI) Additional Paid-In Capital : £26.09 Mil(As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Additional Paid-In Capital?

Verici Dx's quarterly additional paid-in capital increased from Jun. 2022 (£26.75 Mil) to Dec. 2022 (£27.05 Mil) but then stayed the same from Dec. 2022 (£27.05 Mil) to Jun. 2023 (£26.09 Mil).

Verici Dx's annual additional paid-in capital increased from Dec. 2020 (£15.14 Mil) to Dec. 2021 (£15.31 Mil) and increased from Dec. 2021 (£15.31 Mil) to Dec. 2022 (£27.05 Mil).

Verici Dx Additional Paid-In Capital Historical Data

The historical data trend for Verici Dx's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Additional Paid-In Capital Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Additional Paid-In Capital

15.14

15.31

27.05

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23
Additional Paid-In Capital	14.51	15.31	26.75	27.05	26.09

Verici Dx Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Verici Dx Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Verici Dx's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx (LSE:VRCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

VRCDF:USA

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx (LSE:VRCI) Headlines

No Headlines